Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia

优化他非诺喹的剂量以根治东南亚间日疟原虫疟疾

基本信息

  • 批准号:
    10703688
  • 负责人:
  • 金额:
    $ 106.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-08 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY In East Asia and Oceania Plasmodium vivax is the most common cause of malaria. Relapses occur in over half the infections and comprise the main burden of P. vivax malaria. Relapses are the major cause of morbidity, particularly in children and pregnant women. In recent years targeted malaria elimination has driven down Plasmodium falciparum malaria in these populous regions, but P. vivax malaria has re-emerged rapidly because of relapse. Preventing relapse (radical cure) requires administration of an 8-aminoquinoline – which until recently meant a 7-14 day course of primaquine. Tafenoquine is a recently registered slowly eliminated 8- aminoquinoline with the substantial operational advantage of providing single dose radical cure. However, Phase 3 randomized controlled trials showed that the currently recommended 300mg adult dose (~ 5mg/kg) of tafenoquine had low radical curative efficacy against P. vivax malaria. Tafenoquine doses up to 14mg/kg have proved safe and well tolerated in adults and children with >70% G6PD activity. We obtained the individual participant (N= 1102) data from the Phase 3 pre-registration trials (DETECTIVE and GATHER; see Bibliography, references 22-24). Individual patient data meta-analysis (see Bibliography, reference 32) shows clearly that a) the dose response curve is steep around the currently recommended dose (5mg/kg) and b) the odds ratio for P. vivax recurrence (<4 months) is 0.69 (95% CI 0.64 to 0.75; p=10-21) for each mg/kg increase in dose. Thus, increasing the dose by half (i.e., to 7.5mg/kg) is predicted to result in an overall >90% reduction of P. vivax recurrence. To test this prediction, we propose conducting a multi-center double-blind randomized clinical trial in five countries in the Greater Mekong sub-Region. Aim 1 compares the radical curative efficacies of the current tafenoquine dose and a 50% higher dose (e.g., 300mg versus 450mg in persons ≥35kg) in adults and children with acute vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) activity >70%. Relapses will be distinguished from reinfections probabilistically based on parasite genotyping and time to event information. To detect very low-density P. vivax parasitemias which might be suppressed by tafenoquine, ultrasensitive polymerase chain reaction (uPCR) will be performed. Aim 2 assesses plasma, urine, and red blood cell tafenoquine concentrations and explores potential tafenoquine metabolites. Genotyping for CYP2D6 mutations and measurements of methemoglobinemia will be included as exposure correlates of radical curative efficacy. Aim 3 assesses safety and tolerability of the higher tafenoquine dose. Tolerability, gastrointestinal symptoms, hematocrit, and elevated blood methemoglobin concentrations will be monitored. This study will provide definitive evidence to guide tafenoquine dosing for the radical cure of P. vivax malaria. An efficacious, safe and well tolerated single dose anti-relapse therapeutic will substantially improve the treatment of P. vivax malaria and accelerate malaria elimination.
项目摘要 在东亚和大洋洲,间日疟原虫是疟疾最常见的病因。复发率超过一半 间日疟是间日疟的主要传染源。复发是发病的主要原因, 尤其是儿童和孕妇。近年来,有针对性地消灭疟疾已经使 恶性疟原虫疟疾在这些人口稠密地区,但间日疟原虫疟疾迅速重新出现 因为复发。预防复发(根治)需要给予8-氨基喹啉, 直到最近还意味着7-14天的伯氨喹疗程。Tafenoquine是最近注册的缓慢消除的8- 氨基喹啉具有提供单剂量自由基固化的实质操作优点。然而,在这方面, III期随机对照试验显示,目前推荐的300 mg成人剂量(约5 mg/kg) 他非诺喹对间日疟的根治性疗效较低。他非诺喹剂量高达14 mg/kg, 在成人和G6 PD活性>70%的儿童中证明安全且耐受性良好。我们找到了 来自III期预注册试验的参与者(N= 1102)数据(DETECTIVE和GATHER;见 参考书目,参考文献22-24)。个体患者数据荟萃分析(参见参考文献32)显示 显然,a)剂量反应曲线在当前推荐剂量(5 mg/kg)附近陡峭,B) 间日疟原虫复发(<4个月)的比值比为0.69(95% CI 0.64至0.75; p=10-21), 次给药结束因此,将剂量增加一半(即,至7.5mg/kg)预计将导致总体>90%的 P.间日疟复发为了验证这一预测,我们建议进行一项多中心双盲随机 在大湄公河次区域的五个国家进行临床试验。目的1比较根治性疗效 当前他非诺喹剂量的50%和更高剂量的50%(例如,300 mg vs 450 mg(≥ 35 kg的成人) G6 PD活性> 70%的急性间日疟患儿。 复发将根据寄生虫基因分型和至 事件信息。为了检测可能被他非诺喹抑制的极低密度间日疟原虫寄生虫血症, 将进行超灵敏聚合酶链反应(uPCR)。目的2评估血浆、尿液和红细胞 血细胞他非诺喹浓度和探索潜在的他非诺喹代谢物。CYP 2D 6基因分型 高铁血红蛋白血症的突变和测量结果将作为暴露相关的自由基, 疗效目的3评估更高剂量他非诺喹的安全性和耐受性。耐受性, 将监测胃肠道症状、血细胞比容和升高的血液高铁血红蛋白浓度。 本研究将为指导他非诺喹治疗间日疟提供明确的依据。 有效、安全且耐受性良好的单剂量抗复发治疗剂将显著改善患者的复发。 治疗间日疟和加速消灭疟疾。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cindy S Chu其他文献

Primaquine dose and the risk of haemolysis in patients with uncomplicated emPlasmodium vivax/em malaria: a systematic review and individual patient data meta-analysis
伯氨喹剂量与单纯性间日疟/卵形疟患者溶血风险的关系:系统评价和个体患者数据荟萃分析
  • DOI:
    10.1016/s1473-3099(23)00431-0
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
    31.000
  • 作者:
    Megha Rajasekhar;Julie A Simpson;Benedikt Ley;Peta Edler;Cindy S Chu;Tesfay Abreha;Ghulam R Awab;J Kevin Baird;Germana Bancone;Bridget E Barber;Matthew J Grigg;Jimee Hwang;Harin Karunajeewa;Marcus V G Lacerda;Simone Ladeia-Andrade;Alejandro Llanos-Cuentas;Sasithon Pukrittayakamee;Komal R Rijal;Kavitha Saravu;Inge Sutanto;Adugna Woyessa
  • 通讯作者:
    Adugna Woyessa
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated emPlasmodium vivax/em: a systematic review and individual patient data meta-analysis
伯氨喹剂量对单纯性间日疟患者复发风险的影响:系统评价和个体患者数据荟萃分析
  • DOI:
    10.1016/s1473-3099(23)00430-9
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
    31.000
  • 作者:
    Robert J Commons;Megha Rajasekhar;Peta Edler;Tesfay Abreha;Ghulam R Awab;J Kevin Baird;Bridget E Barber;Cindy S Chu;Liwang Cui;André Daher;Lilia Gonzalez-Ceron;Matthew J Grigg;Jimee Hwang;Harin Karunajeewa;Marcus V G Lacerda;Simone Ladeia-Andrade;Kartini Lidia;Alejandro Llanos-Cuentas;Rhea J Longley;Dhelio B Pereira;Adugna Woyessa
  • 通讯作者:
    Adugna Woyessa
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
高铁血红蛋白作为间日疟原虫疟疾中伯氨喹抗催眠子活性的替代标志物:系统评价和个体患者数据荟萃分析
  • DOI:
    10.1101/2024.05.08.24307041
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Ihsan Fadilah;Robert J Commons;N. H. Chau;Cindy S Chu;Nick Day;Gavin C K W Koh;Justin A. Green;M. Lacerda;Alejandro Llanos;E. Nelwan;François H. Nosten;A. Pasaribu;Inge Sutanto;Walter R J Taylor;K. Thriemer;Richard N Price;N. J. White;Kevin Baird;J. A. Watson
  • 通讯作者:
    J. A. Watson
Primaquine for uncomplicated emPlasmodium vivax/em malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis
用于 15 岁以下儿童单纯性间日疟/疟疾的伯氨喹:系统评价和个体患者数据荟萃分析
  • DOI:
    10.1016/s2352-4642(24)00210-4
  • 发表时间:
    2024-11-01
  • 期刊:
  • 影响因子:
    15.500
  • 作者:
    Robert J Commons;Megha Rajasekhar;Elizabeth N Allen;Daniel Yilma;Palang Chotsiri;Tesfay Abreha;Ishag Adam;Ghulam Rahim Awab;Bridget E Barber;Larissa W Brasil;Cindy S Chu;Liwang Cui;Peta Edler;Margarete do Socorro M Gomes;Lilia Gonzalez‑Ceron;Matthew J Grigg;Muzamil Mahdi Abdel Hamid;Jimee Hwang;Harin Karunajeewa;Marcus V G Lacerda;Adugna Woyessa
  • 通讯作者:
    Adugna Woyessa

Cindy S Chu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
  • 批准号:
    2885806
  • 财政年份:
    2023
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
  • 批准号:
    10772386
  • 财政年份:
    2023
  • 资助金额:
    $ 106.79万
  • 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
  • 批准号:
    474619
  • 财政年份:
    2022
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
  • 批准号:
    485965
  • 财政年份:
    2022
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
  • 批准号:
    466358
  • 财政年份:
    2022
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
  • 批准号:
    402040
  • 财政年份:
    2019
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
  • 批准号:
    377313
  • 财政年份:
    2017
  • 资助金额:
    $ 106.79万
  • 项目类别:
    Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
  • 批准号:
    9315111
  • 财政年份:
    2016
  • 资助金额:
    $ 106.79万
  • 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
  • 批准号:
    8734273
  • 财政年份:
    2013
  • 资助金额:
    $ 106.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了